<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> stem cells (<z:chebi fb="11" ids="17437,53115">CSCs</z:chebi>) are initiating cells in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">Colorectal tumours</z:e> undergo epithelial to mesenchymal transition (EMT)-like processes at the invasive front, enabling invasion and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, and recent studies have linked this process to the acquisition of stem cell-like properties </plain></SENT>
<SENT sid="2" pm="."><plain>It is of fundamental importance to understand the molecular events leading to the establishment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> initiating cells and how these mechanisms relate to cellular transitions during <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">tumourigenesis</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We use an in vitro system to recapitulate changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells at the invasive front (mesenchymal-like cells) and central mass (epithelial-like cells) of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We show that the mesoderm inducer BRACHYURY is expressed in a subpopulation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells that resemble invasive front mesenchymal-like cells, where it acts to impose characteristics of <z:chebi fb="11" ids="17437,53115">CSCs</z:chebi> in a fully reversible manner, suggesting reversible formation and modulation of such cells </plain></SENT>
<SENT sid="5" pm="."><plain>BRACHYURY, itself regulated by the oncogene Î²-catenin, influences NANOG and other 'stemness' markers including a panel of markers defining <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-<z:chebi fb="11" ids="17437,53115">CSC</z:chebi> whose presence has been linked to poor patient prognosis </plain></SENT>
<SENT sid="6" pm="."><plain>Similar regulation of NANOG through BRACHYURY was observed in other cells lines, suggesting this might be a pathway common to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells undergoing mesenchymal transition </plain></SENT>
<SENT sid="7" pm="."><plain>We suggest that BRACHYURY may regulate NANOG in mesenchymal-like <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells to impose a 'plastic-state', allowing competence of cells to respond to signals prompting invasion or <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
</text></document>